Effective June 1st according to Bulletin 118, effective June 1st, 2022, EVRYSDIⓇ (risdiplam) will be covered through Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary (link). The specific criteria for reimbursement are in line with recommendations made by CADTH in 2021 and can be requested at the EDS office within Manitoba Health.
Initiation Criteria
1. Pre-symptomatic patients with 2 or 3 copies of the SMN2 gene,
OR
2. Had the disease for <6 months, 2 copies of SMN2, and symptom onset after the first week after birth and on, or before seven months of age.
OR
3. Patients under the age of 18 with symptom onset > 6 months of age, and never achieved the ability to walk independently. †
Stopping Criteria
1. For those pre-symptomatic at initiation: no improvement/maintenance on HINE-2, CHOP INTEND, or HFMSE, OR
2. For those symptomatic at initiation: no maintenance in HINE-2, CHOP INTENT, or HFMSE, OR
3. Permanent invasive ventilation required
“Other patients who do not meet the expanded funding criteria may be considered in exceptional cases.”
No information available at this time.